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 28 
Abstract 29 
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive cancer, with low survival rates and 30 
limited therapeutic options. Thus, the elucidation of signaling pathways involved in PDAC pathogenesis 31 
is essential to identify novel potential therapeutic gene targets. Here, we used a systems approach by 32 
integrating gene and microRNA profiling analyses together with CRISPR/Cas9 technology, to identify 33 
novel transcription factors involved in PDAC pathogenesis. FOXA2 transcription factor was found to be 34 
significantly down-regulated in PDAC relative to control pancreatic tissues. Functional experiments 35 
revealed that FOXA2 has a tumor suppressor function through inhibition of pancreatic cancer 36 
cell growth, migration, invasion and colony formation. In situ hybridization analysis revealed 37 
miR-199a significantly upregulated in pancreatic cancer. Bioinformatics and luciferase analyses 38 
showed that miR-199a negatively regulates directly FOXA2 expression, through binding in its 3’ 39 
untranslated region (UTR).  Evaluation of the functional importance of miR-199 on pancreatic 40 
cancer revealed that miR-199 acts as an inhibitor of FOXA2 expression, inducing an increase in 41 
pancreatic cancer cell proliferation, migration and invasion. Additionally, gene ontology and 42 
network analyses in PANC-1 cells treated with an siRNA against FOXA2 revealed an 43 
enrichment for cell invasion mechanisms through PLAUR and ERK activation. FOXA2 deletion 44 
(FOXA2Δ) by using two CRISPR/Cas9 vectors in PANC-1 cells, induced tumor growth in vivo, 45 
resulting in up-regulation of PLAUR and ERK pathways in FOXA2Δ xenograft tumors. Taken 46 
together, we have identified FOXA2 as a novel tumor suppressor in pancreatic cancer, regulated 47 
directly by miR-199a, enhancing our understanding on how microRNAs interplay with the 48 
transcription factors to affect pancreatic oncogenesis. 49 
 50 
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Introduction 55 
 56 
Pancreatic ductal adenocarcinoma (PDAC) accounts for >85% of all the pancreatic cancer cases. 57 
For all stages combined, the 1- and 5-year relative survival rates are 28% and 7%, respectively. 58 
More than half of patients (53%) are diagnosed at a late stage, where the 1- and 5-year survival 59 
rates reach 15% and 2%, respectively (44). Recently there are significant advances in the 60 
development of novel therapeutics, based on the rational design of targeted therapies directed at 61 
molecular alterations arising in cancer cells (72); however, PDAC remains a lethal disease. Even 62 
gemcitabine, the current standard of care chemotherapeutic, produces only a modest increase in 63 
survival in patients with PDAC (9).  For metastatic disease, the standard of care is a combination 64 
four chemotherapeutic drugs, known as FOLFIRINOX (Folinic Acid, Fluorouracil, Irinotecan 65 
Hydrochloride, Oxaliplatin) (62). These treatments have limited efficacy and significant side 66 
effects, often only marginally improving the quality of life of patients (63). Therefore, there is an 67 
urgent need to identify novel therapeutic target molecules that a play a key role in pancreatic 68 
oncogenesis. 69 
 70 
Premalignant lesions, known as pancreatic intraepithelial neoplasms (PanINs) are of ductal 71 
origin (32) and are thought to be precursors of ductal adenocarcinoma, as they progress toward 72 
increasingly atypical histological stages (40, 51, 55, 68).  Multiple combinations of genetic 73 
mutations are commonly found in pancreatic adenocarcinomas (64). The KRAS gene, located on 74 
chromosome 12p, is one of the most frequently mutated genes in pancreatic cancer. The vast 75 
majority of mutations in this gene are at codon 12, leading to activation of the protein product of 76 
KRAS (33).  KRAS mutations appear to occur very early in pancreatic carcinogenesis, indicating 77 
an important role in early initiation of disease (2). In addition to activating mutations, loss of 78 
function mutations in tumor suppressor genes is also commonly observed in pancreatic 79 
carcinomas.  Loss of function occurs via inactivation mutations, homozygous deletions or DNA 80 
hypermethylation of the promoter areas of tumor suppressor genes, including p16/CDKN2A, 81 
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TP53, and SMAD4 that are inactivated in more than 50% of all pancreatic cancers (1, 30, 31, 58).  82 
Other pathways, involved in PDAC include, the Notch signaling pathway (Abel, 2014), the beta-83 
catenin signaling pathway (46) and the PI3K/AKT signaling pathway (7). Although the role of 84 
different protein signaling pathways has been examined in pancreatic oncogenesis, the role and 85 
function of several transcription factor families has not been evaluated extensively. 86 
 87 
Transcription factors affect downstream gene transcription of signal transduction pathways 88 
triggered by genetic and epigenetic changes linked to the aggressive nature of cancer (60). For 89 
example, the constitutive activation of NF-κB, which regulates the genes involved in many 90 
cellular processes, has also been implicated in the aggressive nature of PDAC (20). Signal 91 
transducer and activator of transcription 3 (STAT3) is activated in primary pancreatic cancer and 92 
is involved in various physiologic functions, including apoptosis, cell cycle regulation, 93 
angiogenesis, and metastasis (12). Negative regulation of STAT3 at the posttranscriptional level 94 
leads to attenuation of cell proliferation and invasion of pancreatic carcinoma (69), highlighting 95 
the importance of understanding transcriptional regulation in pancreatic oncogenesis. In 2012, 96 
Xia et al. identified a transcription factor, Forkhead Box M1 (FOXM1) that is associated with 97 
poor prognosis and could be used as a prognostic molecular marker and therapeutic target for 98 
pancreatic cancer (66).  99 
 100 
In the present study, we sought to identify key transcriptional regulators that play a functional 101 
role in the pathogenesis of pancreatic cancer by performing transcription factor expression 102 
profiling followed by functional characterization of selected transcription factor. The aberrant 103 
expression of hepatocyte nuclear factor family of transcription factors (HNF1, HNF3, HNF4 and 104 
HNF6) have been implicated in a variety of solid tumors including lung, colorectal, 105 
hepatocellular and ovarian carcinoma (25, 43, 45, 49, 50, 73). The least studied hepatocyte 106 
nuclear factor gene family in cancer is HNF3. The hepatocyte nuclear factor 3 gene family 107 
encodes three transcription factors (HNF-3α, HNF-3β, and HNF-3γ) important in the regulation 108 
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of gene expression in normal liver and lung tissue, and were first identified by their ability to 109 
bind to important promoter elements in the α1-antitrypsin and transthyretin genes (13). Our 110 
molecular and functional analysis revealed that HNF-3β, also known as forkhead box protein A2 111 
(FOXA2), acts as a tumor suppressor gene in pancreatic cancer by affecting pancreatic cancer 112 
cell proliferation and invasiveness through regulation of urokinase plasminogen activator surface 113 
receptor (PLAUR) gene. Furthermore, we found that FOXA2 expression is regulated directly by 114 
miR-199, while inhibition of FOXA2 expression by using the CRISPR/Cas9 (clustered regularly 115 
interspaced short palindromic repeats-CRISPR associated nuclease 9) technology increases 116 
tumor growth in pancreatic tumor xenografts. Taken together, our study revealed a novel 117 
microRNA-transcription factor signaling pathway involved in the pathogenesis of pancreatic 118 
oncogenesis.  119 
 120 
 121 
 122 
MATERIALS AND METHODS 123 
 124 
Cell Culture 125 
Human pancreatic cancer cell lines (AsPc-1, BxPC-3, Capan-1, Capan-2, HPAF-II and MIA 126 
PaCa-2, PANC-1) were purchased from ATCC. Human pancreatic cancer cell line PANC-1 was 127 
maintained in DMEM medium (Gibco) supplemented with 10% FBS and 10 units/ml penicillin, 128 
and 100 μg/ml streptomycin. AsPC-1 and BxPC-3 were maintained in RPMI-1640 medium 129 
(Gibco) supplemented with 10%FBS and 10 units/ml penicillin and 100 μg/ml streptomycin. 130 
Capan-1 was maintained in ATCC-formulated Iscove’s Modified Dulbecco’s Medium 131 
supplemented with 10% FBS and 10 units/ml penicillin and 100 μg/ml streptomycin. Capan-2 132 
was maintained in ATCC-formulated McCoy’s 5a Medium Modified supplemented with 10% 133 
FBS and 10 units/ml penicillin and 100 μg/ml streptomycin. HPAF-II was maintained in Eagle’s 134 
Minimum Essential Medium with 10% FBS and 10 units/ml penicillin and 100 μg/ml 135 
streptomycin. MIA PaCa-2 was maintained in DMEM medium (Gibco) supplemented with 10% 136 
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FBS, horse serum to a final concentration of 2.5% and 10 units/ml penicillin and 100 μg/ml 137 
streptomycin.  138 
 139 
RNA from PDAC and control samples 140 
Human pancreatic tissues were obtained from consenting patients in the Department of Surgery 141 
at Stanford University and approved by the Ethics Committee of the Stanford University Medical 142 
School. RNA was extracted from 8 control (adjacent non-tumor) and 14 PDAC tissues using the 143 
TRIzol Reagent (15596-018, Life Technologies) RNA isolation method and were used for gene 144 
profiling. Nineteen control and 17 PDAC tissues were obtained from consenting patients in the 145 
Department of Surgery at the University of California, Los Angeles and approved by the UCLA 146 
Ethics Committee and were used to confirm gene expression array data. 147 
 148 
Transcription factor expression analysis 149 
To identify transcription factors that were differentially expressed in pancreatic ductal 150 
adenocarcinoma, microarray was performed using GeneChip® Human Genome U133 Plus 2.0 151 
Arrays. RNA was isolated from 14 PDAC and 8 control tissues. In the list of top differentially 152 
expressed genes, FOXA2 was found to be down-regulated in PDAC (cut off was 2-fold change, 153 
p<0.05).  154 
 155 
Invasion Assays 156 
We performed invasion assays in PANC-1 and HPAF-II cells at 24 hours under different 157 
transfection conditions with siRNAs or microRNAs for 24 hours. Invasion of matrigel was 158 
conducted using standardized conditions with BD BioCoat Matrigel invasion chambers (BD 159 
Biosciences). Assays were conducted according to manufacturer’s protocol, using 10% FBS as 160 
the chemoattractant. Non-invading cells on the top side of the membrane were removed, while 161 
invading cells were fixed and stained with 0.1 % crystal violet, 16 hours post-seeding. The cells 162 
that invaded through the filter were quantified by counting the entire area of each filter, using a 163 
grid and an Optech microscope at a 20X magnification.  The experiment was repeated three 164 
times and the statistical significance was calculated using Student’s t-test. 165 
 166 
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Migration Assays 167 
PANC-1 and BxPC-3 pancreatic cancer cell lines were used in this assay. The migration assay 168 
was performed by starving cells overnight in media containing 0% FBS. The next day, cells were 169 
re-suspended in media with 0.5% FBS to a concentration of 5×105/ml. The upper chamber was 170 
loaded with 100 μL of cell suspension and the lower chamber was loaded with 500 μL medium 171 
containing 20% FBS as a chemoattractant. The cells on the bottom of each chamber were fixed 172 
with 0.1% glutaraldehyde for 30 min, rinsed briefly with PBS and stained with 0.2% crystal 173 
violet. The number of migrated cells was calculated using 20X magnification and the mean for 174 
each chamber was determined. The results were calculated as the migration rate as compared 175 
with the siRNA negative control (or miRNA-NC) cells. Each experimental condition was 176 
conducted in triplicates and the experiment was repeated three times. 177 
 178 
Colony Formation Assays 179 
PANC-1 cells were transfected with siRNA negative control or siFOXA2#2 for 48 hours. 180 
Triplicate samples of 105 cells from each cell line were mixed 4:1 (v/v) with 2.0% agarose in 181 
growth medium for a final concentration of 0.4% agarose. The cell mixture was plated on top of 182 
a solidified layer of 0.8% agarose in growth medium. Cells were fed every six to seven days with 183 
growth medium containing 0.4% agarose. The number of colonies was counted after 20 days. 184 
The experiment was repeated three times and the statistical significance was calculated using the 185 
Student’s t-test. 186 
 187 
 188 
In situ hybridization 189 
Double-DIG labeled Mircury LNA probes were used for the detection of hsa-miR-199a-3p 190 
(38481-15, Exiqon) with target sequence ACAGUAGUCUGCACAUUGGUUA.  In situ 191 
hybridization protocol was used as previously described (Iliopoulos et al., 2009b) with 192 
modifications. FFPE sections of control pancreatic and PDAC were deparaffinized with xylene 193 
(3x5 min), followed by treatment with serial dilutions of ethanol (3x100%, 2x96% and 3x70%) 194 
and by two changes of DEPC-PBS. Tissues were then digested with proteinase K (15 μg/ml) for 195 
20 min at 37ºC, rinsed with 3xDEPC-PBS. Sections were dehydrated with 3x70%, 2x96% and 196 
2x100% ethanol, air-dried and hybridized for 1 hour with the hsa-miR-199 probe (40nM) or the 197 
 8 
 
double-DIG labeled U6 Control Probe (1nM) (99002-15, Exiqon) diluted in microRNA ISH 198 
buffer (90000, Exiqon) at 52ºC and 53 ºC, respectively. Following hybridization, sections were 199 
rinsed twice with 5XSSC, 2x1XSSC and 3x0.2XSSC, 5 min each, at 52ºC and PBS. The slides 200 
were incubated with blocking solution (11585762001, Roche) for 15 min and then with anti-DIG 201 
antibody (1:800) in 2% sheep serum (013-000-121, Jackson Immunoresearch) blocking solution 202 
for 1 hour at room temperature. Following three washes with PBS, 0.1% Tween-20, slides were 203 
incubated with the AP substrate buffer (NBT-BCIP tablet [11697471001, Roche] in 10 ml of 204 
0.2mM Levamisole [31742, Fluka]) for 2 hours at 30ºC in the dark. The reaction was stopped 205 
with 2 washes of AP stop solution (50mM Tris-HCL, 150mM NaCl, 10mM KCl) and 2 washes 206 
with water. Tissues were counter stained with Nuclear Fast Red for 1 min and rinsed with water. 207 
Sections were dehydrated with 2x70%, 2x96% and 2x100% ethanol and mounted with coverslips 208 
in Eukitt mounting medium (361894G, VWR). Images were captured with a Nikon 80i Upright 209 
Microscope equipped with a Nikon Digital Sight DS-Fi1 color camera, using the NIS-Elements 210 
image acquisition software. All images were captured and processed using identical settings. 211 
 212 
Immunohistochemistry 213 
A pancreas disease spectrum tissue microarray of 103 cases was used (PA2081a, US Biomax, 214 
Inc.) containing 42 cases of pancreatic duct adenocarcinoma, three pancreatic adenosquamous 215 
carcinoma, one pancreatic islet cell carcinoma, six pancreatic metastatic carcinoma, 10 216 
pancreatic islet cell tumor, 11 pancreatic inflammation and 21 adjacent normal pancreatic tissue, 217 
duplicated cores per case.  Immunohistochemical staining for FOXA2 in control and pancreatic 218 
PDACs were deparaffinized with xylene (3x5 min) followed by treatment with serial dilutions of 219 
ethanol (100%, 100%, 95% and 95%, 10 min each) and by two changes of ddH2O. Antigen 220 
unmasking was achieved by boiling the slides (95-99ºC) for 10 min, in 10 mM sodium citrate, 221 
pH 6.0. Sections were rinsed three times with ddH2O, immersed in 3% H2O2 for 20 minutes, 222 
washed twice with ddH2O and once with TBS-T (TBS, 0.1% Tween-20) and blocked for 1 hour 223 
with blocking solution (5% normal goat serum [5425] in TBS-T). FOXA2 (sc-6554, Santa Cruz 224 
Biotechnology) antibody was diluted 1:250 in Signal Stain antibody diluent (8112, Cell 225 
Signaling Technology) and incubated with the sections overnight at 4ºC. Staining for mouse 226 
FOXA2, antibody was diluted 1:1000 in Signal Stain antibody diluent (sc-101060 Santa Cruz 227 
Biotechnology) and incubated with the sections overnight at 4ºC.  Following incubation with the 228 
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antibody, sections were washed three times, 5 minutes each, with TBS-T and incubated for 1 229 
hour at room temperature with SignalStain Boost ([HRP, Rabbit] 8114, Cell Signaling). Sections 230 
were washed three times, 5 minutes 22 each, with TBS-T, and stained with the DAB Peroxidase 231 
Substrate Kit (SK-4100, Vector Laboratories) for 30 minutes, washed and counterstained with 232 
the hematoxylin QS (H-3404, Vector Laboratories). Finally, tissues were dehydrated and 233 
mounted in Eukitt medium. Images were captured with a Nikon 80i Upright Microscope 234 
equipped with a Nikon Digital Sight DS-Fi1 color camera, using the NIS-Elements image 235 
acquisition software. All images were captured and processed using identical settings. 236 
 237 
Real-Time PCR analysis 238 
Quantitative real-time RT-PCR was performed to determine the expression levels of FOXA2 in 239 
17 human PDAC tissues and 19 pancreatic control tissues for detection of miR-199a-3p. RNA 240 
was isolated using TRIzol, according to manufacturer’s instructions (15596-018, Life 241 
Technologies). Real-time RT-PCR was assessed on a CFX384 detection system (BioRad) using 242 
the Exiqon PCR primer sets according to manufacturer’s instructions. MicroRNA expression 243 
levels of miR-199 (204536, Exiqon) were normalized to the levels of U6 small nuclear snRNA 244 
(203907, Exiqon) and 5S rRNA (203906, Exiqon). Reverse transcription was carried out using 245 
the Universal cDNA synthesis kit (203301, Exiqon) and ExiLENT SYBR Green for RT-PCR 246 
(203403, Exiqon). Normalized miRNA levels were quantified relative to the levels of a given 247 
control tissue. Real-time PCR was employed to determine the expression levels of FOXA2 and 248 
PLAUR. Reverse transcription was carried out using iScript cDNA synthesis Kit (1708890, Bio-249 
Rad). Real-time PCR was carried out using the iQ SYBR Green Supermix (1708882, Bio-Rad). 250 
Gene expression levels were normalized to the levels of Glyceraldehyde-3-phosphate 251 
dehydrogenase (GAPDH) and β-actin. Normalized gene expression levels were quantified to the 252 
respective control. The sequences of the primers used are the following: 253 
FOXA2-F: 5’-ATGCACTCGGCTTCCAGTAT-3’ 254 
FOXA2-R: 5’-GTTGCTCACGGAGGAGTAGC-3’ 255 
PLAUR-F: 5’-GCATTTCCTGTGGCTCATC-3’ 256 
PLAUR-R: 5’- CTTTGGACGCCCTTCTTCA-3’ 257 
E-Cadherin-F: 5’-GGATTGCAAATTCCTGCCATTC-3’ 258 
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E-Cadherin-R: 5’-AACGTTGTCCCGGGTGTCA-3’ 259 
GAPDH-F: 5’-ATGTTCGTCATGGGTGTGAA-3’ 260 
GAPDH-R: 5’-GGTGCTAAGCAGTTGGTGGT-3’ 261 
β-actin-F: 5’-CCCAGCACAATGAAGATCAA-3’ 262 
β-actin-R: 5’-ACATCTGCTGGAAGGTGGAC-3’ 263 
IL6-F: 5’- CTCTGGGAAATCGTGGAAATGAG -3’ 264 
IL6-R: 5’-CTGTATCTCTCTGAAGGACTCTG-3’ 265 
 266 
 267 
 268 
Luciferase Assay 269 
MIA PaCa-2 cells were transfected with the reporter vectors carrying the 3′UTR of FOXA2 270 
(S805635, SwitchGear Genomics.  The constructs harbored the seed sequence of miR-199a-3p 271 
(wildtype) or had a mutation of this sequence (miR-199 mutant). At 24 hours, the cells were 272 
transfected with miR-negative control or miR-199 mimic and at 48 h luciferase activity was 273 
measured using the Dual Luciferase Reporter Assay System (E1910, Promega). 274 
 275 
Cell growth Assays 276 
PANC-1 and BxPC-3 pancreatic cancer cell lines were transfected with siFOXA2#2 or miR-199 277 
mimic and their respective control and plated on a 96-well plate (5×102cells/well). Cell growth 278 
was assessed using the Cell-Titer Glo Luminescence Cell Viability Assay (G7571, Promega).  279 
The xCELLigence RTCA SP system utilizes a 96-well microtiter detection device, where the 280 
microelectrode sensor arrays are coated in 96-well microtiter plates and the microtiter plate 281 
detection device is connected to the workstation from the inside of the cell incubator. The 282 
impedance data from the selected well is exported to the computer and analyzed using RTCA 283 
software. A parameter termed cell index is used to quantify cell status based on detected cell-284 
electrode impedance. Cell attachment and proliferation from selected wells of the plate were 285 
monitored and recovered every 15 minutes using the RTCA SP for 120h.  The PANC-1 cells 286 
were transfected with miR-NC or miR-199. 24 hours post-transfection, cells were trypsinized 287 
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and cells were re-suspended at 5×103 cells/100 μL and 5×103 cells were seeded into each well of 288 
the E-plate 96 in quadruplicates.  289 
 290 
Mouse experiments 291 
5x106 PANC-1 control or PANC-1 FOXA2Δ cells were injected subcutaneously in the right 292 
flank of NOD/SCID mice (n= 10 mice/group). Tumor growth was monitored every seven days 293 
for a total period of 64 days. Tumor volumes were calculated by the equation V (mm3) = axb2/2, 294 
where “a” is the largest diameter and b is the perpendicular diameter. In addition, paraffin 295 
embedded tissue sections from pancreatic tissues from male 3-month and 9-month old, male, 296 
KrasG12D+/-p48-Cre+/- (KC) mice, were provided by Dr. Guido Eibl’s laboratory (15). All the 297 
mouse studies were approved by the University of California Institutional Animal Care and Use 298 
Committee and conformed to the US National Institutes of Health Guide for the Care and Use of 299 
Laboratory Animals. 300 
 301 
Western blot analysis 302 
Protein samples were subjected to SDS PAGE and transferred to polyvinylidene difluoride 303 
membranes in 25 mM Tris, 192 mM glycine. Membranes were blocked with 5% nonfat dry milk 304 
in PBS, 0.05% Tween-20 and probed with antibodies (1:1000) followed by corresponding  305 
horseradish peroxidase-labeled secondary antibodies (1:1000). Blots were developed with ECL 306 
reagent (T) and exposed in Eastman Kodak Co. 440 Image Station.  307 
 308 
 309 
Antibodies and reagents 310 
Antibodies 311 
Two different antibodies against FOXA2 were used. One was used for western blotting 312 
experiments (8189, Cell Signaling) and the other (sc-6554, Santa Cruz Biotechnology) for 313 
immunohistochemical analysis. PLAUR antibody was used for western blotting experiments 314 
(9692, Cell Signaling). Additionally, phospho-p44/42 MAPK (Erk1/2)(Thr202/Tyr204) was used 315 
for western blotting in PANC-1 and HPAF –II cell lines (4370, Cell Signaling) along with total 316 
ERK antibody (4695, Cell Signaling), as well as total AKT (4691S, Cell Signaling) and 317 
phospho-AKT T308 (13038S, Cell Signaling) and phosphor-AKT S473 (4060S, Cell Signaling). 318 
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Additionally, CREB and GAPDH antibodies were used as loading controls (9104, Cell Signaling 319 
and 5174, Cell Signaling, respectively).  320 
Small interfering RNAs 321 
The following siRNAs were used in this study: siRNA negative control (siNC #2, 4390847, Life 322 
Technologies) and two different siRNAs against FOXA2 (siFOXA2#1, s6691, Life 323 
Technologies) and (siFOXA2#2, s6692, Life Technologies). A single siRNA against PLAUR 324 
was siPLAUR used in this study (s10614, Life Technologies).  325 
 326 
FOXA2 Overexpression Vector  327 
MiaPaCa-2 cells were transfected with vector plasmids as controls (Origene, PS100001) or 328 
plasmids for overexpression of FOXA2 (Origene, RC211408) according to manufacturer’s 329 
protocol.  330 
 331 
MicroRNAs 332 
The following microRNAs were used in this study: miRVana miRNA mimic, negative control #1 333 
(miRNC, 4464059, Life Technologies) and miR-199 miRVana miRNA mimic (4464066 334 
miRVana miRNA mimic, Life Technologies).   335 
 336 
3’UTR FOXA2 Vector  337 
pLightSwitch_3UTR for FOXA was purchased from SwitchGear Genomics (S805635, 338 
SwitchGear Genomics), containing the miR-199a-3p predicted binding site.   339 
 340 
CRISPR/Cas9 system 341 
The FOXA2 human gene knockout kit via CRISPR was ordered from OriGene (KN204066). 342 
Clones were selected using 2μg/ml puromycin. 343 
Statistical Analysis 344 
All experiments were performed in triplicate unless other-wise stated. Statistical analyses were 345 
performed with the use of Origin software, version 8.6. Student’s t-test was used to examine the 346 
statistical difference in FOXA2 and miR-199 expression between control and PDAC tissues. The 347 
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correlation significance was determined by means of Spearman and Pearson correlation analyses. 348 
A P-value of < 0.05 was considered statistically significant (*P < 0.05, **P< 0.01, ***P<0.001). 349 
 350 
Ingenuity Network Software (IPA) 351 
Gene network was constructed and important hubs were identified using Ingenuity Pathway 352 
Analysis (IPA; Ingenuity Systems, Mountain View, CA) based on the differentially expressed 353 
genes identified after inhibition of FOXA2 expression by siRNA FOXA2#2 in X pancreatic 354 
cancer cell line. IPA is a robust and expertly curated database containing updated information on 355 
more than 20,000 mammalian genes and proteins, 1.4 million biological interactions, and 100 356 
canonical pathways incorporating over 6,000 discreet gene concepts. This information is 357 
integrated with relevant databases such as Entrez-Gene and Gene Ontology. The experimental 358 
data sets were used to query the IPA and to compose a set of interactive networks taking into 359 
consideration canonical pathways, the relevant biological interactions, and the cellular and 360 
disease processes. Pathways of highly interconnected genes were identified by statistical 361 
likelihood using the following equation: 362 
 363 
Where N is the number of genes in the network of which G are central node genes, for a pathway 364 
of s genes of which f are central node genes. C(n,k) is the binomial coefficient. We considered 365 
statistically significant networks those with a score greater than 5 (p value <10−5). 366 
 367 
 368 
 369 
 370 
 371 
 372 
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RESULTS 373 
FOXA2 transcription factor is down-regulated in human pancreatic cancers. 374 
To evaluate the role of the human transcriptome in pancreatic oncogenesis, first we examined the 375 
expression levels of all the known transcription factors by performing gene profiling analysis in 376 
eight pancreatic control and fourteen PDAC tissues. This analysis revealed 43 transcription 377 
factors that were deregulated (>1.5 fold) in PDAC relative to control tissues (Figure 1A, Table 378 
1). Interestingly, among the top differentially expressed transcription factors were FOXA2 379 
(HNF-3β), HNF-1β and HNF-6, three members of the hepatocyte nuclear factor family of 380 
transcription factors (Figure 1B). Although the HNF family members are known to be involved 381 
in liver oncogenesis (25), their role in pancreatic oncogenesis has not been evaluated. The 382 
profiling analysis showed FOXA2 mRNA to be highly down-regulated in PDAC relative to 383 
control tissues, suggesting a potential tumor suppressor role in PDAC.   To further validate the 384 
gene expression findings, we performed quantitative real-time PCR to examine FOXA2 mRNA 385 
expression levels in 14 control and 14 PDAC tissues in a second cohort of pancreatic cancer 386 
patients. Consistent with our initial findings, FOXA2 mRNA levels were significantly 387 
downregulated in PDAC (Figure 1C). In addition, we performed immunohistochemical (IHC) 388 
analysis for FOXA2 in 63 human tissue sections, including 42 PDAC, 21 control pancreatic 389 
tissues and found that 31/42 (74%) of PDAC tumors had no expression of FOXA2, while 390 
FOXA2 was expressed in all of the control tissues (Figure 1D), further suggesting a potential 391 
tumor suppressor role of FOXA2 in PDAC.  In order to investigate the role of FOXA2 392 
expression in pancreatic oncogenesis, we performed immunohistochemical analysis for FOXA2 393 
in 3-month and 9-month old KC mice. Consistent with the human data, expression of FOXA2 394 
was decreased in the 9-month old mice compared to the 3-month old mice (Figure 1E), 395 
suggesting that FOXA2 expression is decreased during pancreatic oncogenesis. Overall, all these 396 
data show that FOXA2 mRNA and protein levels are decreased in PDAC.  397 
 398 
 399 
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 400 
FOXA2 has tumor suppressor properties in PDAC.  401 
To study the functional role of FOXA2 in pancreatic cancer, we screened a panel of seven 402 
(PANC-1, BxPC-3, HPAF-II, Capan-1, Capan-2, AsPC-1, MiaPaCa-2) different human 403 
pancreatic cancer cell lines for FOXA2 expression. Out of the seven cell lines investigated, 404 
PANC-1, BxPC-3 and HPAF-II expressed FOXA2 mRNA and were selected to perform further 405 
molecular studies by manipulating FOXA2 expression levels. We silenced FOXA2 expression 406 
by using two different siRNAs in two pancreatic cancer cell lines that exhibited increased 407 
FOXA2 levels (PANC-1 and BxPC-3). Cell growth analysis was studied and comparisons were 408 
performed relative to the cells transfected with an siRNA negative control (Figure 2A). 409 
Although siRNA#2 had a higher knockdown efficiency than siRNA#1 against FOXA2 (data not 410 
shown), when cells were transfected with either siRNA#1 or siRNA#2, a statistically significant 411 
increase in cell growth was observed in both PANC-1 and BxPC-3 cell lines, 48 hours post 412 
transfection (Figure 2A). Due to the higher knockdown efficiency, siRNA#2 was used in the 413 
follow-up experiments to manipulate FOXA2 levels in vitro. Specifically, FOXA2 inhibition by 414 
siRNA#2 significantly increased the ability of PANC-1 cells to form colonies in soft agar 415 
(Figure 2B). To further explore the functional role of FOXA2 in pancreatic cancer cell 416 
properties, we performed cell migration and invasion assays in PANC-1 (Figure 2C and D) and 417 
BxPC-3 cells (Figure 2E and F). A statistically significant higher number of migrating and 418 
invading cells were observed upon FOXA2 knockdown, suggesting that inhibition of FOXA2, 419 
promotes pancreatic oncogenesis. In order to explore the role of FOXA2 overexpression on 420 
invasion, FOXA2 was overexpressed in MiaPaCa-2 cells, a human pancreatic cancer cell line 421 
that does not express basal levels of FOXA2. There was a statistically significant difference in 422 
invasion upon FOXA2 overexpression, with a significant decrease in invasion upon FOXA2 423 
overexpression compared to control (Figure 2G).  424 
 425 
 426 
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MiR-199a negatively regulates FOXA2 expression through binding in its 3’UTR. 427 
We were interested in identifying the molecular mechanism involved in the suppression of 428 
FOXA2 expression in pancreatic cancer. Initial DNA methylation analysis (Infinium 429 
HumanMethylation450 BeadChip assay) on 20 PDAC human tissues and 15 cancer adjacent 430 
normal tissues revealed that the FOXA2 promoter region was not differentially methylated in 431 
PDAC (data not shown), suggesting that DNA methylation is not the molecular mechanism 432 
responsible for FOXA2 reduced expression in pancreatic cancer. According to our previous 433 
studies, microRNAs have been found to be essential regulators of transcription factors involved 434 
in oncogenesis (34). Bioinformatics analysis by using the TargetScan algorithm revealed that 435 
miR-199a-3p has sequence complementarity in the position of 275-81 nt of the 3’UTR of 436 
FOXA2 (Figure 3A).  To examine the direct interaction between miR-199a and FOXA2, we 437 
performed a 3’UTR luciferase assay. MiR-199 was overexpressed in Mia PaCa-2 cells that were 438 
co-transfected with a construct harboring the 3’UTR of FOXA2 under luciferase activity. We 439 
found that miR-199a overexpression reduced FOXA2 3’UTR luciferase activity compared to 440 
control and point mutation of the miR-199a binding site in the 3’UTR FOXA2 luciferase vector 441 
abolished the suppressive effects of miR-199a (Figure 3B). To further validate the interaction 442 
between miR-199a and FOXA2 in vitro, miR-199 was overexpressed in PANC-1 cells.  We 443 
examined FOXA2 mRNA and protein levels, and found that FOXA2 levels significantly 444 
decreased in miR-199a-overexpressing pancreatic cancer cells (Figure 3C, D). Taken together, 445 
these findings suggest that miR-199a is a direct regulator of FOXA2 expression in pancreatic 446 
cancer.  447 
 448 
MiR-199a has an oncogenic function in PDAC. 449 
Next, we were interested in investigating the relevance of miR-199a in human pancreatic cancer. 450 
We performed real-time PCR analysis in 19 control and 17 PDAC tissues and found a 451 
statistically significant up-regulation of miR-199 expression in PDAC compared to control 452 
(Figure 4A). In order to examine the up-regulation of miR-199a in histological tissues, we 453 
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performed in situ hybridization on a tissue microarray containing 25 cases of pancreas 454 
adenocarcinoma with matched cancer adjacent tissue.  In situ hybridization revealed 17/25 (68%) 455 
of adenocarcinomas highly expressed miR-199a (bottom panel), while it was not expressed in 456 
control tissues (upper panel) (Figure 4B). To explore the functional role of miR-199 in 457 
pancreatic oncogenesis we used the xCELLigence technology to monitor cell growth over a 458 
period of 120 hours, with a measurement taken every 15 minutes. This assay showed that miR-459 
199a significantly increases the growth of PANC-1 cells (Figure 4C). Cell growth was also 460 
performed with the same experimental samples using the CellTiter-Glo Luminescent Cell 461 
Viability assay. MiR-199a overexpression led to a 50% increase in PANC-1 cell growth 462 
compared to cells transfected with a microRNA negative control (Figure 4C).  To further assess 463 
the functional effects of miR-199a overexpression in pancreatic cancer, we performed migration 464 
and invasion assays in PANC-1 cells and found a statistically higher number of migrating and 465 
invading cells in the miR-199a-overexpressing PANC-1 cells relative to cells transfected with 466 
the microRNA negative control (Figure 4D and E). 467 
 468 
FOXA2-regulated gene network in PDAC. 469 
Our data revealed that FOXA2 has tumor suppressor properties in PDAC and its expression is 470 
regulated by miR-199a. To evaluate the molecular mechanisms that are regulated by FOXA2 471 
suppression in PDAC and identify its downstream gene targets, we transiently knocked down 472 
FOXA2 using siFOXA2#2 in PANC-1 cells and its corresponding negative control, 473 
demonstrating an 80% inhibition of FOXA2 mRNA expression levels (Figure 5A). Next, we 474 
performed gene profiling analysis and found that 372 genes were up-regulated, while 552 were 475 
down-regulated (924 genes in total) in siFOXA2#2 PANC-1 cells relative to siRNA negative 476 
control by using a cut-off of p<0.05 and a fold change of 2 (Figure 5B).  The Ingenuity Pathway 477 
Analysis (IPA) software was employed to perform signaling pathway analysis.  The results 478 
revealed statistically significant enrichment for the cell movement/invasion pathway, cell 479 
proliferation, PI3K/AKT and MAPK signaling pathways (Figure 5C). To further evaluate these 480 
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findings we performed gene network analysis by using the 924 differentially expressed genes in 481 
the IPA software network analysis and found that the most significant (p value =10-42) gene 482 
network was involved in cellular invasion having PLAUR, extracellular signal-regulated kinases 483 
(ERK), and phosphoinositide 3-kinase (PI3K) as central nodes, consistent with our pathway 484 
analysis (Figure 5D). Consistent with IPA network analysis data, inhibition of FOXA2 in 485 
HPAF-II cells leads to activation of ERK, demonstrated by ERK phosphorylation (Figure 5E), 486 
suggesting that FOXA2 suppression directly or indirectly leads to ERK activation. Interestingly, 487 
PLAUR is a gene known to be related to cancer cell invasiveness and motility (14, 29, 67).  To 488 
further validate the gene network findings, we examined PLAUR expression levels by real-time 489 
PCR after FOXA2 inhibition by siRNA#2. Consistent with our initial findings, FOXA2 490 
inhibition resulted in a significant increase in PLAUR mRNA levels in PANC-1 cells (Figure 491 
5F). To examine if PLAUR is mediating FOXA2 effects on pancreatic cancer cell invasiveness, 492 
we performed an invasion assay knocking down either FOXA2 or both FOXA2 and PLAUR by 493 
siRNAs in HPAF-II cells, a pancreatic cell line that expresses basal levels of both FOXA2 and 494 
PLAUR. We observed a significant increase in invasion by knockdown of FOXA2 and this 495 
increase in invasion was completely reversed when cells were transfected with both an siRNA 496 
against FOXA2 and an siRNA against PLAUR (Figure 5G), suggesting that PLAUR is a major 497 
mediator of FOXA2 effects on pancreatic cell invasiveness.  Taken together, these data suggest 498 
that FOXA2 regulates pancreatic cell invasiveness through regulation of PLAUR expression 499 
levels.  500 
Furthermore, it is known that microRNAs have multiple downstream gene targets and recent 501 
studies have shown that the NF-kB pathway, which is affected by miR-199a, cross-talks with the 502 
FOXA2 signaling pathway (49). To shed some light on the potential cross talk between FOXA2 503 
and other common oncogenic pathways like nuclear factor-κB (NF-κB), we looked at the 504 
expression of IL6, a downstream target of NF-kB, upon transient inhibition of FOXA2 in the 505 
BxPC-3 cell line. Upon knockdown of FOXA2 with siRNA#2, there is a significant increase in 506 
IL6 levels (Figure 5H), indicating activation of the NF-kB pathway. 507 
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Generating a FOXA2Δ pancreatic cell line using the CRISPR/Cas9 system. 508 
We observed the effects of FOXA2 inhibition of expression in vitro through a series of 509 
functional and gene expression assays. In order to study the effects of FOXA2 deletion in vivo, 510 
we developed a cell line with a permanent knock-out of FOXA2 at the chromosomal level 511 
(FOXA2Δ). We used the CRISPR/Cas9 system, where we co-transfected PANC-1 cells with two 512 
FOXA2 gRNA vectors, containing two different target sequences (Figure 6A) and the 513 
corresponding donor control vector. After clonal selection in puromycin, we validated FOXA2Δ 514 
at the protein level (Figure 6B) and also found a significant increase in PLAUR mRNA levels in 515 
FOXA2Δ compared to control (Figure 6C), consistent with our siRNA experimental setting. 516 
Next, we examined the phosphorylation levels of ERK and AKT by western blot and found both 517 
kinases to be activated in FOXA2Δ compared to control, consistent with our gene network 518 
analysis (Figure 6D and E). Conclusively, this data demonstrates the high efficiency of the 519 
CRISPR/Cas9 system, its consistency with the siRNA system, providing us with a powerful tool 520 
to study the role of FOXA2 in vivo.  521 
 522 
CRISPR/Cas9 FOXA2 Inhibition suppresses pancreatic tumor growth in vivo. 523 
To further support the role of FOXA2 as a tumor suppressor gene in pancreatic cancer, we 524 
wanted to test its properties in vivo. We performed subcutaneous injections in NOD/SCID mice 525 
with either FOXA2Δ PANC-1 (5x105 cells) or its corresponding PANC-1 control cell line 526 
(n=10/group).  On day 64, mice were sacrificed and tumors were isolated. The FOXA2Δ tumor 527 
volumes (mm3) and weight (g) were significantly larger than the PANC-1 control tumors 528 
(Figure 7A, B and C).  On day 64, RNA was isolated from each tumor and quantitative real-529 
time PCR showed that FOXA2 was not expressed in the FOXA2Δ tumors relative to controls 530 
(Figure 7D). Furthermore, in accordance with our in vitro findings, FOXA2Δ tumors showed 531 
increased PLAUR mRNA levels (Figure 7E). Moreover, E-cadherin levels decreased in 532 
FOXA2Δ tumors, indicating FOXA2 may also regulate cellular motility (Figure 7F). Taken 533 
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together, the in vivo data suggest that inhibition of FOXA2 increases the pancreatic 534 
tumorigenicity and aggressiveness. 535 
 536 
 537 
DISCUSSION 538 
Our study revealed FOXA2 as a novel tumor suppressor gene in pancreatic cancer. FOXA2 is a 539 
455-amino acid member of the forkhead class of DNA-binding proteins and contains a highly 540 
conserved winged-helix DNA-binding domain (56). FOXA2 is a transcription factor that was 541 
initially identified in hepatocytes, where it binds in the promoter areas of important liver-542 
enriched genes transthyretin, alpha 1-antitrypsin and albumin (13, 19, 28). It is required for the 543 
formation of the node, notochord, nervous system, and endoderm-derived structures (19, 36). In 544 
adulthood, FOXA2 has been shown to control metabolic homeostasis and to contribute to insulin 545 
resistance (65).   546 
 547 
In the last decade, several studies have implicated the role of FOXA2 in solid tumors. FOXA2 548 
has been found to be expressed in all types of neuroendocrine lung tumors (37) and shown to be 549 
a key regulator in colorectal liver metastases (43).  We found that FOXA2 inhibition induces 550 
cancer cell invasiveness, consistent with its function in other cancers. Specifically, in human 551 
lung cancer cells, upon TGF-β1 treatment, FOXA2 levels are decreased, leading to activation of 552 
Slug transcription, thus inducing epithelial-mesenchymal transition (EMT) and promoting 553 
invasion (61).  More recently, Liu et al. demonstrated FOXA2 phosphorylation by TNFα-554 
induced IKKα stimulates the NOTCH1 pathway to promote liver cell proliferation and growth, 555 
indicating FOXA2 suppression by phosphorylation plays an important role in TNFα mediated 556 
tumorigenesis (49).   557 
 558 
Although dysregulation of FOXA2 has been directly linked to the progression of certain cancers, 559 
this class of transcription factors can paradoxically serve as both tumor suppressors and 560 
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oncogenes (41). Very little is known about the roles of FOXA2 in invasion and tumor metastasis 561 
in pancreatic cancer. Our study identifies the transcription factors differentially expressed in 562 
PDAC and shows that FOXA2, and other hepatocyte nuclear factors, are significantly 563 
downregulated in human PDAC. Knockdown of FOXA2 led to a significant increase in cellular 564 
growth, migration, invasion and colony formation, indicating that FOXA2 harbors tumor 565 
suppressive properties.  566 
 567 
Recent advances in pancreatic cancer biology have emerged important roles for microRNAs 568 
(miRNAs) in regulating tumor responses. MiRNAs, a class of non-coding RNAs, have emerged 569 
as critical players in cancer initiation and progression by modulating many pathological aspects 570 
related to tumor development, growth, metastasis, and drug resistance (48). Studies have found 571 
that miRNAs control many cellular processes through involvement in development, proliferation, 572 
the stress response, apoptosis, cell cycle progression, and differentiation (3, 5, 6, 16, 47). The 573 
major function of miRNAs is to post-transcriptionally regulate gene expression depending on 574 
recognition of complementary sequence residing in target mRNAs. Several key oncogenic 575 
miRNAs have been identified in pancreatic cancer, including miR-483-3p, miR-155, miR-576 
21/miR-221, miR-27a, miR-371-5p and miR-21/miR-23a/miR-27a. Inhibition of oncogenic 577 
miRNAs reduces functional properties of pancreatic oncogenesis (18, 23, 24, 26, 52, 57).  Our 578 
data indicate that miR-199a-3p plays an oncogenic role, with a significant increase in expression 579 
in PDAC compared to control. In the last decade, investigations have revealed that the 580 
expression of miRNA-199 is altered in several human cancers (22, 42, 70). Specifically, the 581 
expression of miRNA-199 is increased in ovarian cancer cells and cervical carcinomas (22, 70) 582 
in accordance to our data in PDAC. Specifically, overexpression of miR-199 in pancreatic cancer 583 
cells led to an increase in pancreatic cell growth, migration and invasion in vitro, demonstrating 584 
miR-199 oncogenic properties in pancreatic cancer. 585 
 586 
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We found that miR-199a-3p directly regulates FOXA2 mRNA and protein expression, through 587 
binding in its 3’UTR. Furthermore, recent studies have identified additional downstream targets 588 
of miR-199 in other cancer types. For example, miR-199 targets Frizzled type 7 receptor 589 
(FZD7), one of the most important Wnt receptors involved in cancer development and 590 
progression (59). Additionally, mTOR, c-MET, IKKβ, MET proto-oncogene and CD44 have 591 
also been identified as direct targets of miR-199, playing a major role in cancer initiation and 592 
progression in different types of cancer (10, 17, 21, 27, 39).  593 
 594 
Conventionally, loss of function genetic screens in cultured cells is mainly conducted with the 595 
aid of RNA interference (RNAi) libraries (8, 71). However, RNAi could only partially and 596 
temporary suppress gene expression and thus its application is limited to knockdown screens (8, 597 
54). Moreover, due to the endogenous nature of the RNAi pathway, it often incurs pervasive off-598 
target events because of the extensive endogenous interactions. These off-target effects may 599 
confound the interpretation of screen results (35). Recently, the emergence of CRISPR/Cas9 600 
technique offers a novel and versatile platform for genetic screen studies (4, 11, 53).  For these 601 
reasons, we chose the highly efficient CRISPR/Cas9 deletion system to permanently knock-out 602 
FOXA2 in a pancreatic cancer cell line to study its effects in vivo. In addition, inhibition of 603 
FOXA2 expression levels by CRISPR/Cas9 in vitro, led to the activation of PLAUR gene, which 604 
is known to be involved in cancer invasiveness (38). Importantly, these findings were consistent 605 
with our data where FOXA2 expression was suppressed by siRNA, suggesting that the 606 
CRISPR/Cas9 system is very effective to block gene expression in cancer cells. Taken together, 607 
our study has revealed a novel signaling pathway, consisting of the miR-199 and FOXA2 tumor 608 
suppressor gene involved in pancreatic oncogenesis.    609 
 610 
 611 
 612 
 613 
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FIGURE LEGENDS 820 
Figure 1.  821 
FOXA2 transcription factor is down-regulated in human pancreatic cancers. A. Pancreatic 822 
cancer transcription factor transcriptome. Heatmap showing unsupervised clustering of 823 
expression Z-scores of mRNA expression of 105 probes from 43 transcription factor genes in 22 824 
human pancreatic tissue (control =7 and cancer =15). B. Expression levels of hepatocyte nuclear 825 
factor family transcription factors (FOXA2, HNF-1β and HNF-6) from the list of 43 826 
transcription factors differentially expressed in PDAC. C. FOXA2 mRNA levels by real-time 827 
PCR in 28 human pancreatic tissue (control =14 and cancer =14).  D. Immunohistochemical 828 
staining for human FOXA2 in control (top panel) and PDAC tissue (bottom panel).  E. 829 
Immunohistochemical staining for mouse FOXA2 in 3-month old (top panel) and 9-month old 830 
 28 
 
KrasG12D+/-p48-Cre+/- (KC) mice (bottom panel). The experiments have been performed in 831 
triplicate and all data are represented as mean ± SD. ***P<0.001, **P<0.01, *P<0.05. 832 
 833 
Figure 2. 834 
FOXA2 has tumor suppressor gene properties in PDAC. A. Relative percent cell growth 835 
measured in PANC-1 and BxPC-3 treated for 48 h with siRNA negative control (siRNA NC) or 836 
two different siRNAs against FOXA2 (siFOXA2#1 and siFOXA2#2) using the Cell-Titer Glo 837 
Luminescence Cell Viability Assay. B. Soft agar colony formation assay of PANC-1 cells treated 838 
for 48 h with siRNA NC or siFOXA2#2. Colonies (mean ± SD) 50 mm were counted using a 839 
microscope 20 days later. C.  Transwell cell migration assay in PANC-1 cells transfected with 840 
siRNA NC or siFOXA2#2, migrating across 8 mm micropore membranes. D. Invasion through 841 
matrigel-coated transwell inserts in PANC-1 cells transfected with siRNA NC or siFOXA2#2. E. 842 
Transwell cell migration assay in BxPC-3 cells transfected with siRNA NC or siFOXA2#2, 843 
migrating across 8 mm micropore membranes. F. Invasion through matrigel-coated transwell 844 
inserts in BxPC-3 cells transfected with siRNA NC or siFOXA2#2.  G. Invasion through 845 
matrigel-coated transwell inserts in MiaPaCa-2 cells transfected with control vector (control) or 846 
FOXA2 overexpression vector (FOXA2 OE).  The experiments have been performed in triplicate 847 
and all data are represented as mean ± SD. ***P<0.001, **P<0.01, *P<0.05. 848 
 849 
Figure 3.  850 
FOXA2 as a direct target of miR-199a-3p in PDAC. A.Sequence complimentarity between 851 
miR-199a-3p seed sequence and the 3’UTR of FOXA2. B. FOXA2 3’UTR luciferase activity in 852 
MIA PaCa-2 cells transfected with miR-NC or miR-199, 48 h post transfection. MiR-199 853 
sequence was wildtype (miR 199) or mutated (miR mutant). C. FOXA2 relative mRNA levels in 854 
PANC-1 cell line 24 h post transfection with miR-199 mimic. D. Western blot showing FOXA2 855 
protein levels in PANC-1 cell line 72 h post transfection with miR-199 mimic. The experiments 856 
have been performed in triplicate and all data are represented as mean ± SD. ***P<0.001, 857 
**P<0.01, *P<0.05. 858 
 859 
Figure 4.   860 
MiR-199 has an oncogenic function in PDAC. A. MiR-199 mRNA levels in human pancreatic 861 
control (n=19) and cancer tissue (n=17). B. In situ hybridization miR-199 in human pancreatic 862 
control and cancer tissue under 10X and 20X magnification. C. Cell proliferation in Panc-1 cells 863 
24 h post transfection with miR negative control (miR-NC) or miR-199 mimic (miR-199) using 864 
the xCELLigence system. PANC-1 cells were seeded at a density of 5x103 cells/well in 96-well 865 
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E-plates and monitored for 120 h. D. Percentage cell growth measured in BxPC-3 cells treated 866 
with miR-NC or miR-199 for 24 h then plated and measured 48 h later using the Cell-Titer Glo 867 
Luminescence Cell Viability Assay. E. Transwell cell migration assay in PANC-1 cells 868 
transfected with miR-NC or miR-199.  F. Invasion through matrigel-coated transwell inserts in 869 
PANC-1 cells transfected with miR-NC or miR-199. The experiments have been performed in 870 
triplicate and all data are represented as mean ± SD. ***P<0.001, **P<0.01, *P<0.05. 871 
 872 
Figure 5. 873 
FOXA2-regulated gene network in PDAC. A. Relative FOXA2 mRNA levels in PANC-1 cells 874 
transfected with siRNA NC or siFOXA2#2 for gene profiling studies, duplicate experimental 875 
samples were performed. B. Heatmap indicating expression levels of 372 genes up-regulated and 876 
552 genes down-regulated in siRNA NC compared to siFOXA2#2 samples in PANC-1 cell line. 877 
C. Ingenuity Pathway Analysis (IPA) reveals statistically significant enrichment for the cell 878 
movement/invasion pathway, cell proliferation, PI3K/AKT and MAPK signaling pathways. D. 879 
Gene network analysis by using the 924 differentially expressed genes in the IPA software 880 
network found the most significant (p value =10-42) gene network was involved in cellular 881 
invasion having as central nodes PLAUR, ERK, PI3K, consistent with our gene ontology 882 
analysis. E. Western blot indicating phosphorylation of ERK, total ERK and CREB in PANC-1 883 
cells treated with siRNA NC or siFOXA2#2. F. PLAUR mRNA levels in HPAF-II cells treated 884 
with siRNA NC or siFOXA2#2. G.  Invasion through matrigel-coated transwell inserts in HPAF-885 
II cells transfected with siRNA NC, siFOXA2#2 or both siFOXA2#2 and siPLAUR. H. Relative 886 
mRNA levels of IL6, assessed by rt-PCR in BxPC-3 cells transfected with siRNA NC or 887 
siFOXA2#2.The experiments have been performed in triplicate and all data are represented as 888 
mean ± SD. ***P<0.001, **P<0.01, *P<0.05. 889 
 890 
Figure 6. 891 
Generating a FOXA2Δ pancreatic cell line using the CRISPR/Cas9 system.  A. Sequences of 892 
FOXA2 gRNA vectors. PANC-1 cells were transfected with either 1.) two gRNA vectors and 893 
donor vector (donor vector not shown) referred to as FOXA2Δ or 2.) a scramble vector and a 894 
donor vector (scramble vector and donor vector not shown) referred to as PANC-1 control. B. 895 
Western blot for PANC-1 control and FOXA2Δ generated cell lines. C. PLAUR mRNA 896 
expression levels in PANC-1 control and FOXA2Δ cell lines. D. Western blot indicating 897 
phosphorylation of ERK and total ERK plus loading control in PANC-1 control and FOXA2Δ 898 
cell lines. E. Western blot indicating phosphorylation of AKT at two phosphorylation sites 899 
(Ser473 and Thr308) and total AKT plus loading control in PANC-1 control and FOXA2Δ cell 900 
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lines. The experiments have been performed in triplicate and all data are represented as mean ± 901 
SD. ***P<0.001, **P<0.01, *P<0.05. 902 
 903 
Figure 7. 904 
CRISPR/Cas9 FOXA2 Inhibition suppresses pancreatic tumor growth in vivo. A. At day 64, 905 
tumor volumes (mm3) were measured in PANC-1 control and FOXA2Δ (n=10/group) tumors. B. 906 
At day 64, tumors were excised and tumor weight (g) was measured in PANC-1 control and 907 
FOXA2Δ tumors. C. At day 64, PANC-1 control and FOXA2 tumors were excised and 908 
photographed, pictured with ruler (mm). D. At day 64, RNA was isolated from tumors and 909 
FOXA2 mRNA levels were examined in PANC-1 control and FOXA2Δ tumors. E. PLAUR 910 
mRNA levels were examined in PANC-1 control and FOXA2Δ tumors. F. Relative E-cadherin 911 
mRNA levels in PANC-1 control and FOXA2Δ tumors (n=10/group). The experiments have 912 
been performed in triplicate and all data are represented as mean ± SD. ***P<0.001, **P<0.01, 913 
*P<0.05. 914 
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Figure 7 
Transcription Factor Name Fold Change (PDAC vs Control) 
ARNTL2 1.830414193 
AHR 1.770715552 
BHLHE40 1.620227569 
CSDC2 -1.746860866 
ELF4 2.026515581 
ESRRG -2.499329116 
FOXA2 -1.556944005 
FOXF2 1.777107854 
FOXL1 1.861434191 
FOXP2 -1.520345843 
GATA4 -1.824959917 
GLIS3 -1.563211851 
HHEX -1.648626826 
HMGA2 1.806947596 
HNF1B 1.627896229 
HOXA3 1.751809197 
HOXB2 1.593110965 
HOXB6 1.549874116 
HOXB7 2.557724696 
HOXC9 1.683238922 
ID1 1.653506642 
KLF15 -2.700062809 
KLF4 1.524845007 
KLF5 1.728963085 
KLF7 1.564062549 
LEF1 1.913189882 
MAF 1.58038649 
MXD1 1.633748967 
NR5A2 -3.26744002 
ONECUT1 -2.764584396 
PDX1 -1.60514131 
PPARG 1.802035985 
PRDM1 1.995993975 
PRDM16 -1.858238085 
PRDM5 -1.554285542 
PRRX1 1.57618735 
PROX1 -2.480756568 
SOX6 -1.615514705 
TFAP2A 2.652273186 
TWIST1 1.921317868 
VDR 1.755868703 
ZBTB16 -1.687271795 
Table 1. Differentially expressed TFs in PDAC vs controls 
